title: Efficacy and toxicity profiles of two chemoradiotherapies for stage II laryngeal cancer - a comparison between late course accelerated hyperfractionation (LCAHF) and conventional fractionation (CF).
abstract: OBJECTIVE
  To evaluate the treatment results of late course accelerated hyperfractionation (LCAHF) compared with conventional fractionation (CF) for stage II laryngeal cancer.
  
  
  METHODS
  Fifty-nine consecutive patients treated for stage II laryngeal cancer were retrospectively reviewed. Thirty-two patients underwent LCAHF, twice-daily fractions during the latter half with a total dose of 69 Gy. Twenty-seven patients received CF of 70 Gy.
  
  
  RESULTS
  The local control rates (LCRs), overall survival (OS), and disease-specific survival (DSS) at 5 years were 80.6%, 74.0%, and 90.4%, respectively, after LCAHF and 64.7%, 68.2%, and 90.5%, respectively, after CF. There were no significant differences in LCR, OS, and DSS (p = .11, 0.68, and 0.69, respectively). In a small number of patients with supraglottic cancer, LCAHF was associated with a significantly higher LCR at 5 years compared with CF (100% vs. 41.7%; p = .02).
  
  
  CONCLUSIONS
  This is the first report that compared the results of LCAHF and CF for stage II laryngeal cancer. We could not find significant differences in LCR, DSS, and OS rates between LCAHF and CF groups. Although in a small number of patients with supraglottic cancer, LCAHF may improve the LCR compared with CF.
authors.affiliation: a Department of Diagnostic and Interventional Radiology/Radiation Oncology , Osaka City University Graduate School of Medicine , Osaka , Japan.
authors.forename: Eiichiro
authors.identifier: http://orcid.org/0000-0002-8489-8668
authors.initials: E
authors.lastname: Okazaki
authors.affiliation: b Department of Otolaryngology , Osaka City University Graduate School of Medicine , Osaka , Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Matsushita
authors.affiliation: c Department of Internal Medicine , Ishikawa Clinic , Osaka , Japan.
authors.forename: Mari
authors.initials: M
authors.lastname: Tashiro
authors.affiliation: d Department of Radiation Oncology , Osaka City General Hospital , Osaka , Japan.
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Shimatani
authors.affiliation: e Department of Radiation Oncology , Tane General Hospital , Osaka , Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Ishii
authors.affiliation: a Department of Diagnostic and Interventional Radiology/Radiation Oncology , Osaka City University Graduate School of Medicine , Osaka , Japan.
authors.forename: Masako
authors.initials: M
authors.lastname: Hosono
authors.affiliation: b Department of Otolaryngology , Osaka City University Graduate School of Medicine , Osaka , Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Oishi
authors.affiliation: b Department of Otolaryngology , Osaka City University Graduate School of Medicine , Osaka , Japan.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Teranishi
authors.affiliation: b Department of Otolaryngology , Osaka City University Graduate School of Medicine , Osaka , Japan.
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Iguchi
authors.affiliation: a Department of Diagnostic and Interventional Radiology/Radiation Oncology , Osaka City University Graduate School of Medicine , Osaka , Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Miki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy; D059248:Chemoradiotherapy / Q000009:adverse effects* / Q000379:methods*; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D012189:Retrospective Studies
keywords: Late course accelerated hyperfractionation; accelerated hyperfractionation; concurrent chemoradiotherapy; laryngeal cancer